Surveillance of HIV-1 drug resistance in Xinjiang: high prevalence of K103N in treatment-naïve individuals
- 19 Downloads
To identify transmitted and acquired HIV-1 drug resistance mutations in Xinjiang, China, we collected the peripheral blood of 50 treated and 50 treatment-naïve HIV-1-infected individuals in this region. We successfully amplified 36 reverse transcriptase and 42 protease gene sequences of HIV-1 from 51 individuals and identified mutations associated with resistance to reverse transcriptase (RT) and protease (PR) inhibitors (RTIs and PIs) according to Stanford Drug Resistance Database. Among the drug-treated individuals, the results showed that K103N in the RT region was the most frequent mutation, found in 67% (6/9) of the cases, followed by M184V with 56% (5/9). Five individuals had both nucleoside and non-nucleoside reverse transcriptase inhibitor resistance mutations after more than 12 months of treatment. Among the untreated individuals, 33% (9/27) were found to harbor drug resistance mutations in the RT gene. K103N occurred at the highest rate, accounting for 22% (6/27), followed by P225H (7%) and Y188L (4%). Neither of the two groups showed any major resistance mutations to PIs. Our study revealed that the prevalence of drug resistance was relatively high in Xinjiang and that K103N occurred at the highest rate. These results suggest that it is important to carry out HIV drug resistance testing, especially for the K103N mutation in the RT region, before and during the treatment process. This study may help to guide ART strategies in the Xinjiang region.
The authors would like to thank the Key Laboratory on Emerging Infectious Diseases and Biosafety in Wuhan and The Core Facility and Technical Support, Wuhan Institute of Virology.
ZS, YC, TL, BS, RY and conceived and designed the experiments; AA, JM, XL, XM, CJ and GB collected the samples; YC, TL and TY performed the experiments; YC analyzed the data; ZS, YC, BS and RY wrote and edited the paper. All authors have read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors of the current study declare no conflict(s) of interest.
The study was approved by the Ethics Committees of the Sixth People’s Hospital of Xinjiang Uygur Autonomous Region and Wuhan Institute of Virology.
Informed consent was obtained from all individual participants included in the study.
The accession numbers of the sequences analyzed in this study are MF325036-MF325086.
- 1.Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toni TD, Touré-Kane C, Truong LX, Delaporte E (2013) Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis 58:99–109CrossRefPubMedGoogle Scholar
- 2.AIDS Professional Group, Society of Infection Diseases CMA (2016) Forth edition of the guidelines for diagnosis and treatment of HIV/AIDSGoogle Scholar
- 7.Dong Y, Wang L, He C, Zuo H, Wang F, Liao L, Guan X, Liu W, Zhao J, Xing H (2015) Research on HIV subtype and drug resistance transmission in Xinjiang in 2010–2013. Chin J AIDS STD 1:20–23Google Scholar
- 9.Ni J, Chen J, Zhang Y, Jin T, Wang F, Hu X, Dong Y (2012) Analysis of epidemic status of HIV/AIDS in Xinjiang. Bull Dis Control Prev 27(2):1–3Google Scholar
- 10.Zuo H, Liao L, Sun L, Zhang Y, Xing H (2016) Survey on transmitted HIV-1 drug resistance in Urumqi, Xinjiang in 2014. Chin J AIDS STD 22:586–588Google Scholar
- 11.Li J (2010) HIV-1 drug resistance mutations. Chin J AIDS STD 2:195–200Google Scholar
- 15.Liu C, Sun D, Sun G, Liu J, Zhu Q, Tian S, Yang W, Xue X, Wu Y, Wang Z (2015) Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011. AIDS Res Ther 12:22CrossRefPubMedPubMedCentralGoogle Scholar
- 17.National H (2015) 2015 China AIDS Response Progress Report. http://www.unaids.org.cn/en/index/index.asp
- 18.Rhee S-Y, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TFR, Aghokeng AF (2015) Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis. PLoS Med 12:e1001810CrossRefPubMedPubMedCentralGoogle Scholar
- 21.van de Vijver DA, Wensing AM, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix M-L, Costagliola D, De Luca A (2006) The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. JAIDS J Acquir Immune Defic Syndr 41:352–360CrossRefPubMedGoogle Scholar
- 22.Wainberg MA, Brenner BG, Turner D (2005) Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 49:1671–1678CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Wang F, Tao J, Hu X, Ni M (2015) Research of drug-resistance of patients with HIV-1 in Ili Prefecture, Xinjiang. Bull Dis Control Prev 30:4–6Google Scholar
- 26.Wittkop L, Günthard HF, De Wolf F, Dunn D, Cozzi-Lepri A, De Luca A, Kücherer C, Obel N, Von Wyl V, Masquelier B (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11:363–371CrossRefPubMedGoogle Scholar
- 28.Zhang Y, Wang F, Jin T, Ni M (2014) Research on HIV-1 incidence among drug users and their partners in Xinjiang province between 2009 and 2011. Mod Prev Med 6:1105–1107Google Scholar